These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27599876)

  • 1. Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER.
    Subbiah IM; Wheler JJ; Hess KR; Hong DS; Naing A; Fu S; Kurzrock R; Tsimberidou AM
    Int J Cancer; 2017 Jan; 140(1):208-215. PubMed ID: 27599876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial outcomes in older patients with advanced solid tumours.
    Khan KH; Yap TA; Ring A; Molife LR; Bodla S; Thomas K; Zivi A; Smith A; Judson I; Banerji U; de Bono JS; Kaye SB
    Br J Cancer; 2016 Feb; 114(3):262-8. PubMed ID: 26757260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
    Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
    World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.
    Wheler J; Tsimberidou AM; Hong D; Naing A; Jackson T; Liu S; Feng L; Kurzrock R
    Cancer; 2009 Mar; 115(5):1091-9. PubMed ID: 19165805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment.
    Garrido-Laguna I; Janku F; Falchook GS; Fu S; Hong DS; Naing A; Aaron J; Wang X; Kies M; Kurzrock R
    Clin Cancer Res; 2010 Aug; 16(15):4031-7. PubMed ID: 20525754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.
    Gounder MM; Nayak L; Sahebjam S; Muzikansky A; Sanchez AJ; Desideri S; Ye X; Ivy SP; Nabors LB; Prados M; Grossman S; DeAngelis LM; Wen PY
    J Clin Oncol; 2015 Oct; 33(28):3186-92. PubMed ID: 26282642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Age on Clinical Outcomes in Phase 1 Trial Participants.
    Mahipal A; Denson AC; Djulbegovic B; Lush R; Kumar A; Juan TH; Schell MJ; Sullivan DM
    Cancer Control; 2015 Apr; 22(2):235-41. PubMed ID: 26068771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience.
    Wheler J; Tsimberidou AM; Moulder S; Cristofanilli M; Hong D; Naing A; Pathak R; Liu S; Feng L; Kurzrock R
    Clin Breast Cancer; 2010 Feb; 10(1):46-51. PubMed ID: 20133258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.
    Roberts TG; Goulart BH; Squitieri L; Stallings SC; Halpern EF; Chabner BA; Gazelle GS; Finkelstein SN; Clark JW
    JAMA; 2004 Nov; 292(17):2130-40. PubMed ID: 15523074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience.
    Wong HH; Barton C; Acton G; McLeod R; Halford S
    Eur J Cancer; 2016 Oct; 66():9-16. PubMed ID: 27514008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consideration of older patients for enrollment in phase 1 clinical trials: Exploring treatment related toxicities and outcomes.
    Buechel M; McGinnis A; Vesely SK; Wade KS; Moore KN; Gunderson CC
    Gynecol Oncol; 2018 Apr; 149(1):28-32. PubMed ID: 29605046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials.
    Subbiah IM; Falchook GS; Kaseb AO; Hess KR; Tsimberidou AM; Fu S; Subbiah V; Hong DS; Naing A; Piha-Paul SA; Akmal O; Janku F; Kurzrock R
    Oncotarget; 2015 Sep; 6(29):28453-62. PubMed ID: 26164085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials.
    Chihara D; Lin R; Flowers CR; Finnigan SR; Cordes LM; Fukuda Y; Huang EP; Rubinstein LV; Nastoupil LJ; Ivy SP; Doroshow JH; Takebe N
    Lancet; 2022 Aug; 400(10351):512-521. PubMed ID: 35964611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do elderly patients benefit from enrollment into Phase I Trials?
    Tai WM; Lim C; Ahmad A; Ong WS; Choo SP; Lim WT; Tan EH; Kanesvaran R; Tan DS
    J Geriatr Oncol; 2015 May; 6(3):241-8. PubMed ID: 25779876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience.
    Vaklavas C; Tsimberidou AM; Wen S; Hong D; Wheler J; Ng CS; Naing A; Uehara C; Wolff RA; Kurzrock R
    Cancer; 2011 Jan; 117(1):77-85. PubMed ID: 20737567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
    Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
    Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy.
    Kossai M; Duchemann B; Boutros C; Caramella C; Hollebecque A; Angevin E; Gazzah A; Bahleda R; Ileana E; Massard C; Vielh P; Soria JC; Besse B
    Lung Cancer; 2015 Sep; 89(3):306-10. PubMed ID: 26160757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
    Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.